Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering. The clinical-stage biotech company also said it plans to grant the underwriters a 30-day option to purchase up to an additional 4,615,384 of the shares being offered.